USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
diroximel fumarate: treatment of multiple sclerosis
ingenol disoxate: treatment of actinic keratosis
omirsen: treatment of hematologic malignancies
prexigbersen: treatment of hematologic malignancies, inflammation and autoimmune disease
relatlumab: treatment of cancer
gosuranezumab: treatment of progressive supranuclear palsy (PSP)
otamilast: treatment of atopic dermatitis, topical agent
rosuranezumab: treatment of progressive supranuclear palsy (PSP)
bravilizumab: treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)
cofetuzumab: treatment of oncology
emplumab: treatment of cancer
etsantuzumab: treatment of oncology
evispectinib: treatment of cancer
hafnium oxide: radiation sensitizer
metamide methyl fumarate: treatment of multiple sclerosis, psoriasis
mirikizumab: treatment of autoimmune diseases
otanvimilast: treatment of atopic dermatitis, topical agent
pegilodecakin: treatment of advanced solid tumors
ralaniten: treatment of prostate cancer
rasdelumab nesotigen: treatment of malignancies expressing NY-ESO-1
setocabtagene pirtaretroleucel: treatment of leukemia
talditermant alfa: treatment of duchenne muscular dystrophy, spinal muscular atrophy, ALS
tibulizumab: treatment of autoimmune disorders
tracaronase: treatment of spinal cord injury